Definition
Androgen deprivation therapy (ADT) has been a mainstay in prostate cancer therapy. After an excellent clinical response to ADT, however, prostate cancer returns as a therapy resistant and deadly form, resulting in a short survival time of 18–24 months. This form of prostate cancer, now known as castration-resistant prostate cancer (CRPC), often metastasizes to the bone and results in the clinical symptoms of pain. A great challenge is the discovery of new chemotherapy drugs that can increase overall survival of patients with recurrent CRPC.
Cross-References
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Schwab, M. (2015). Castration-Resistant Prostate Cancer. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6802-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_6802-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences